Market closedNon-fractional
Praxis Precision Medicines/PRAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Ticker
PRAX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
82
Website
praxismedicines.com
PRAX Metrics
BasicAdvanced
$684M
Market cap
-
P/E ratio
-$13.65
EPS
2.88
Beta
-
Dividend rate
Price and volume
Market cap
$684M
Beta
2.88
Financial strength
Current ratio
15.121
Quick ratio
14.853
Long term debt to equity
0.464
Total debt to equity
0.968
Management effectiveness
Return on assets (TTM)
-46.65%
Return on equity (TTM)
-85.25%
Valuation
Price to revenue (TTM)
167.387
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-3.704
Growth
Revenue change (TTM)
221.38%
Earnings per share change (TTM)
-76.10%
3-year earnings per share growth
-42.69%
What the Analysts think about PRAX
Analyst Ratings
Majority rating from 7 analysts.
PRAX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-20.00%
Net income
-$40M
47.39%
Profit margin
-9,875.00%
84.24%
PRAX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$7.35
-$2.70
-$2.97
-$2.84
-
Expected
-$9.83
-$5.25
-$3.19
-$2.08
-$2.40
Surprise
-25.24%
-48.57%
-6.75%
36.35%
-
PRAX News
AllArticlesVideos
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $684M as of July 05, 2024.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of July 05, 2024.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Praxis Precision Medicines stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.